Immunological aspects of cancer chemotherapy

@article{Zitvogel2008ImmunologicalAO,
  title={Immunological aspects of cancer chemotherapy},
  author={L. Zitvogel and L. Apetoh and F. Ghiringhelli and G. Kroemer},
  journal={Nature Reviews Immunology},
  year={2008},
  volume={8},
  pages={59-73}
}
Accumulating evidence indicates that the innate and adaptive immune systems make a crucial contribution to the antitumour effects of conventional chemotherapy-based and radiotherapy-based cancer treatments. Moreover, the molecular and cellular bases of the immunogenicity of cell death that is induced by cytotoxic agents are being progressively unravelled, challenging the guidelines that currently govern the development of anticancer drugs. Here, we review the immunological aspects of… Expand

Paper Mentions

Interventional Clinical Trial
This study aims to evaluate for the first time in Colombia the immunogenicity and safety of autologous DCs as enhancers of the immune response in patients with ductal breast cancer who… Expand
ConditionsBreast Cancer Female
InterventionBiological
Interventional Clinical Trial
Patients with specific metastatic cancers who failed prior therapeutic regimes will be treated with NDV for at least a year or until disease progression. The study will measure… Expand
ConditionsGlioblastoma, Neuroblastoma, Sarcoma
InterventionBiological
Effect of Chemotherapy on the Tumor Microenvironment and Anti-tumor Immunity
TLDR
An understanding of the interactions between cytotoxic therapies and the immune system and the tumor microenvironment is crucial for the rational development of combination treatments of immunotherapy with conventional or targeted therapies to achieve a synergistic antitumor effect and improved treatment outcomes. Expand
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
TLDR
The present review aims to summarize the immune-mediated effects of chemotherapeutic agents and their clinical relevance, the biological and clinical features of immune checkpoint blockers and finally, the preclinical and clinical rationale for novel therapeutic strategies combining anticancer agents and immune checkpoint blocker. Expand
[The anti-tumor immune response in breast cancer: Update and therapeutic perspectives].
TLDR
The immunosurvelliance, immunoselection and the immunosubversion concepts involved in the control and evasion of breast carcinoma are precise and therapeutic strategies for the restauration of anti-tumor immunity are developed. Expand
Immune parameters affecting the efficacy of chemotherapeutic regimens
TLDR
It is surmised that immune-relevant biomarkers may guide personalized therapeutic interventions including compensatory measures to restore or improve anticancer immune responses. Expand
Immunological off-target effects of standard treatments in gastrointestinal cancers.
  • A. Duffy, T. Greten
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2014
TLDR
This review summarizes the immune aspects of currently employed therapies-cytotoxic chemotherapeutics, biologic agents and interventional radiologic procedures-in solid tumor malignancies with a particular focus on those agents used in gastrointestinal cancers. Expand
Contribution of the immune system to the chemotherapeutic response
TLDR
An understanding of the immunological events occurring in both animal models and patients undergoing chemotherapy will guide decisions for the development of appropriate combinations and scheduling for the integration of chemotherapy with immunotherapy. Expand
Myeloid-derived suppressor cells: therapeutic modulation in cancer.
TLDR
Improved mechanistic understanding of factors promoting their development, activation and mechanisms of immune suppression are being translated into novel therapeutic approaches, and will be summarized herein. Expand
Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies.
TLDR
Data suggests that HMGB1- and TLR4-dependent immune responses elicited by conventional cancer treatment may increase the probability to achieve a durable therapeutic success. Expand
Chemotherapy and radiotherapy: cryptic anticancer vaccines.
TLDR
The molecular identity of the multiple checkpoints that dictate the success of "immunogenic chemotherapy" at the levels of the drug, of the tumor cell and of the host immune system are discussed. Expand
Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer
TLDR
This review discusses several possible mechanisms of the combined effect of immunotherapy and chemotherapy of cancer and examines various aspects of this issue such as the combination of different treatment options, the dosage for each arm of treatment, and the timing and sequence of the administration of these treatments. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 127 REFERENCES
Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy.
TLDR
Gemcitabine does not appear to be detrimental to specific antitumor cellular immunity and may be useful in combination chemo-immunotherapy protocols, in contrast, vaccination protocols requiring a humoral immune response for maximal efficacy may be compromised in patients treated with gem citabine. Expand
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy
TLDR
It is shown that the release of the high mobility group box 1 protein by dying tumor cells is mandatory to license host dendritic cells (DCs) to process and present tumor antigens, and this knowledge may be clinically exploited to predict the immunogenicity and hence the efficacy of chemotherapeutic regimens. Expand
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
TLDR
Evidence is provided that chemotherapy has the capacity to augment cellular antitumor immunity, a finding with wider implications for the management of treatment-resistant solid tumors. Expand
The immunological effects of taxanes
TLDR
Taxanes are immunostimulatory against neoplasms, supporting the idea that these agents suppress cancer through several mechanisms and not solely through inhibiting cell division. Expand
Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
TLDR
A previously unrecognized pathway for the activation of tumor antigen–specific T-cell immunity that involves secretion of the high-mobility-group box 1 (HMGB1) alarmin protein by dying tumor cells and the action of HMGB1 on Toll-like receptor 4 (TLR4) expressed by dendritic cells (DCs) is described. Expand
Immunotherapy and chemotherapy — a practical partnership
TLDR
How recent data have altered the way the authors understand how dying tumour cells, particularly those killed by chemotherapy, engage with antitumour immune responses has significant implications for the development of new protocols combining chemotherapy with immunotherapy. Expand
Immune response against dying tumor cells.
TLDR
This chapter examines the way the modality of tumor cell death and/or the immune system can be manipulated so dying tumor cells become immunogenic and clear evidence in favor of tumor escape mechanisms is provided. Expand
Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer.
TLDR
CIT has become less toxic, is being handled on a cost-effective outpatient basis, while maintaining similar objective response rates to earlier inpatient treatments, and will probably have an increasing role in the management of patients with specific cancers. Expand
Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines.
TLDR
Combination doxorubicin and vaccine treatment of established CT26 cancers increased cure rates over that achieved with either agent alone, while combination cyclophosphamide and vaccines treatment of animals carrying CT26 tumors was no better in curing the animals than drug treatment alone. Expand
Cancer despite immunosurveillance: immunoselection and immunosubversion
TLDR
At the early stages of carcinogenesis, cell-intrinsic barriers to tumour development seem to be associated with stimulation of an active antitumour immune response, whereas overt tumours development seems to correlate with changes in the immunogenic properties of tumour cells. Expand
...
1
2
3
4
5
...